Bruce Coate

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Clive Ballard, Carol Banister, Zunera Khan et al. · The Lancet Neurology · 2018 · 188 citations

Medicine, Pharmacology, Psychiatry +15

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis

Clive Ballard, Stuart Isaacson, Roger Mills et al. · Journal of the American Medical Directors Association · 2015 · 56 citations

Medicine, Pharmacology, Pharmacotherapy +16

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications

Alberto J. Espay, Michael T. Guskey, James C. Norton et al. · Movement Disorders · 2018 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Total and unbound darunavir pharmacokinetics in pregnant women infected with <scp>HIV</scp>‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

C D Zorrilla, Rodney Wright, OO Osiyemi et al. · HIV Medicine · 2013 · 50 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms

Clive Ballard, James M. Youakim, Bruce Coate et al. · The Journal of Prevention of Alzheimer s Disease · 2019 · 40 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17